Critical Review: Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP)

Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Redhill Biopharma and Indaptus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Indaptus Therapeutics	N/A	-612.59%	-243.78%

Analyst Ratings

This is a summary of recent recommendations and price targets for Redhill Biopharma and Indaptus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1	0	0	0	1.00
Indaptus Therapeutics	1	0	1	0	2.00

Indaptus Therapeutics has a consensus price target of $140.00, indicating a potential upside of 3,756.75%. Given Indaptus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than Redhill Biopharma.

Volatility & Risk

Redhill Biopharma has a beta of 4.57, indicating that its share price is 357% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Institutional & Insider Ownership

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 20.8% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Redhill Biopharma and Indaptus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$8.04 million	0.68	-$8.27 million	N/A	N/A
Indaptus Therapeutics	N/A	N/A	-$15.02 million	($37.66)	-0.10

Redhill Biopharma has higher revenue and earnings than Indaptus Therapeutics.

Summary

Redhill Biopharma beats Indaptus Therapeutics on 6 of the 10 factors compared between the two stocks.

About Redhill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.